TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee

ROCKVILLE, Md., May 11, 2015 /PRNewswire/ — TissueGene Inc. is pleased to announce that Dr. Moon Jong Noh, VP of Research & Development, will present phase 2 clinical data for TG-C at both the 12^th World Congress of the International Cartilage Repair Society (ICRS) and the 18^th meeting of the American Society of Gene & Cell Therapy (ASGCT).  Dr. Noh presented a poster at ICRS on Saturday May 9^th, and he will follow with an oral presentation at ASGCT on Friday May 15^th.

TG-C is an allogeneic (donor) cell therapy involving human chondrocytes (cartilage cells) that have been genetically modified to produce the therapeutic growth factor TGF-beta1 and has been developed to induce cartilage regeneration in patients with osteoarthritis.  In a primary analysis of the phase 2 clinical study results, TG-C showed a statistically significant improvement over placebo in the change from baseline in both pain (VAS) and function (IKDC) scores. The MRI analysis showed cartilage regeneration evidence in selected TG-C treated patients. On the basis of this compelling phase 2 data, TissueGene is preparing to initiate phase 3 trials of TG-C in patients with osteoarthritis of the knee.